Advanced Search
Current and Breaking News for Professionals, Consumers and Media

Click here to learn how to advertise on this site and for ad rates.

FDA Approval Author: Staff Editor Last Updated: Sep 7, 2017 - 10:06:33 PM

FDA Approves New 800mg PREZISTA® (darunavir) Tablet

By Staff Editor
Nov 9, 2012 - 5:14:32 PM

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust

Email this article
 Printer friendly page
( - TITUSVILLE, N.J., Nov. 9, 2012 -- Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved a new 800mg tablet of PREZISTA(®) (darunavir) for once daily oral administration for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations. PREZISTA(®) is always taken with and at the same time as ritonavir with food and in combination with other HIV medicines.

The new tablet strength will allow patients taking PREZISTA(®) once daily to reduce the number of PREZISTA(®) tablets by half, taking one 800mg tablet instead of two 400mg tablets once a day with ritonavir 100mg and other antiretroviral medications.

The 800mg tablet is expected to be available shortly. Janssen plans to discontinue the PREZISTA(®) 400mg tablet, which will become obsolete as a result of the introduction of the 800mg tablet. To help physicians and patients transition to the new tablet, Janssen will provide educational materials about the new tablet to pharmacies. PREZISTA(®) 800mg tablets will be added to medicines covered by the Janssen Therapeutics Patient Savings Program as well as those covered by the Johnson & Johnson Patient Assistance Foundation.

"The single 800mg tablet provides an option for a reduced pill burden and reflects our ongoing commitment to offer more treatment options for the diverse population of people living with HIV," said Bryan Baugh, MD, Medical Director at Janssen Therapeutics.


PREZISTA(®) (darunavir) is a prescription medicine. It is one treatment option in the class of HIV (human immunodeficiency virus) medicines known as protease inhibitors. PREZISTA(®) is always taken with and at the same time as ritonavir (Norvir(®)), in combination with other HIV medicines for the treatment of HIV infection in adults. PREZISTA(®) should also be taken with food.

-- The use of other medicines active against HIV in combination with
PREZISTA(®)/ritonavir (Norvir(®)) may increase your ability to fight
HIV. Your healthcare professional will work with you to find the right
combination of HIV medicines
-- It is important that you remain under the care of your healthcare
professional during treatment with PREZISTA(®)
PREZISTA(®) does not cure HIV infection or AIDS and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. You should remain under the care of a doctor when using PREZISTA(®).

Please read Important Safety Information below, and talk to your healthcare professional to learn if PREZISTA(®) is right for you.

Important Safety Information

What is the most important information I should know about PREZISTA(®)?

-- PREZISTA(®) can interact with other medicines and cause serious side
effects. See "Who should not take PREZISTA(®)?"
-- PREZISTA(®) may cause liver problems. Some people taking PREZISTA(®),
together with Norvir(®) (ritonavir), have developed liver problems
which may be life-threatening. Your healthcare professional should do
blood tests before and during your combination treatment with
PREZISTA(®). If you have chronic hepatitis B or C infection, your
healthcare professional should check your blood tests more often because
you have an increased chance of developing liver problems
-- Tell your healthcare professional if you have any of these signs and
symptoms of liver problems: dark (tea-colored) urine, yellowing of your
skin or whites of your eyes, pale-colored stools (bowel movements),
nausea, vomiting, pain or tenderness on your right side below your ribs,
or loss of appetite
-- PREZISTA(®) may cause a severe or life-threatening skin reaction or
rash. Sometimes these skin reactions and skin rashes can become severe
and require treatment in a hospital. You should call your healthcare
professional immediately if you develop a rash. However, stop taking
PREZISTA(®) and ritonavir combination treatment and call your
healthcare professional immediately if you develop any skin changes with
these symptoms: fever, tiredness, muscle or joint pain, blisters or skin
lesions, mouth sores or ulcers, red or inflamed eyes, like "pink eye."
Rash occurred more often in patients taking PREZISTA(®) and raltegravir
together than with either drug separately, but was generally mild
Who should not take PREZISTA(®)?

-- Do not take PREZISTA(®) if you are taking the following medicines:
alfuzosin (Uroxatral(®)), dihydroergotamine (D.H.E.45(®), Embolex(®),
Migranal(®)), ergonovine, ergotamine (Cafergot(®), Ergomar(®)),
methylergonovine, cisapride (Propulsid(®)), pimozide (Orap(®)), oral
midazolam, triazolam (Halcion(®)), the herbal supplement St. John's
wort (Hypericum perforatum), lovastatin (Mevacor(®), Altoprev(®),
Advicor(®)), simvastatin (Zocor(®), Simcor(®), Vytorin(®)), rifampin
(Rifadin(®), Rifater(®), Rifamate(®), Rimactane(®)), sildenafil
(Revatio(®)) when used to treat pulmonary arterial hypertension,
indinavir (Crixivan(®)), lopinavir/ritonavir (Kaletra(®)), saquinavir
(Invirase(®)), boceprevir (Victrelis(TM)), or telaprevir (Incivek(TM))
-- Before taking PREZISTA(®), tell your healthcare professional if you are
taking sildenafil (Viagra(®), Revatio(®)), vardenafil (Levitra(®),
Staxyn(®)), tadalafil (Cialis(®), Adcirca(®)), atorvastatin
(Lipitor(®)), rosuvastatin (Crestor(®)), pravastatin (Pravachol(®)),
or colchicine (Colcrys(®), Col-Probenecid(®)). Tell your healthcare
professional if you are taking estrogen-based contraceptives (birth
control). PREZISTA(®) might reduce the effectiveness of estrogen-based
contraceptives. You must take additional precautions for birth control,
such as condoms
This is not a complete list of medicines. Be sure to tell your healthcare professional about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

What should I tell my doctor before I take PREZISTA(®)?

-- Before taking PREZISTA(®), tell your healthcare professional if you
have any medical conditions, including liver problems (including
hepatitis B or C), allergy to sulfa medicines, diabetes, or hemophilia
-- Tell your healthcare professional if you are pregnant or planning to
become pregnant, or are breastfeeding
-- The effects of PREZISTA(®) on pregnant women or their unborn babies
are not known. You and your healthcare professional will need to
decide if taking PREZISTA(®) is right for you
-- Do not breastfeed. It is not known if PREZISTA(®) can be passed to
your baby in your breast milk and whether it could harm your baby.
Also, mothers with HIV should not breastfeed because HIV can be
passed to your baby in the breast milk
What are the possible side effects of PREZISTA(®)?

-- High blood sugar, diabetes or worsening of diabetes, and increased
bleeding in people with hemophilia have been reported in patients taking
protease inhibitor medicines, including PREZISTA(®)
-- Changes in body fat have been seen in some patients taking HIV
medicines, including PREZISTA(®). The cause and long-term health
effects of these conditions are not known at this time
-- Changes in your immune system can happen when you start taking HIV
medicines. Your immune system may get stronger and begin to fight
infections that have been hidden
-- The most common side effects related to taking PREZISTA(®) include
diarrhea, nausea, rash, headache, stomach pain, and vomiting. This is
not a complete list of all possible side effects. If you experience
these or other side effects, talk to your healthcare professional. Do
not stop taking PREZISTA(®) or any other medicines without first
talking to your healthcare professional
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Please refer to the ritonavir (Norvir(®)) Product Information (PI and PPI) for additional information on precautionary measures.

Please see full Prescribing Information for more details, available at

About Janssen Therapeutics
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in HIV and other infectious diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Headquartered in Titusville, New Jersey, Janssen Therapeutics, Division of Janssen Products, LP, is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Visit for more information and follow us on Twitter at @JanssenUS.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Products, LP and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; manufacturing difficulties or delays; and product efficacy or safety concerns. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at, or on request from Johnson & Johnson. Neither Janssen Products, LP nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.

Web Site:


For advertising and promotion on please contact Mike McCurdy: [email protected] or 877-634-9180 is syndicated worldwide, to thousands of journalists in all media, and health-related websites.

Top of Page

FDA Approval
Latest Headlines

+ FDA Warns About Illegal Use of Injectable Silicone for Body Contouring and Associated Health Risks
+ FDA Warns of Potential Contamination in Multiple Brands of Drugs, Dietary Supplements
+ FDA Approves New Treatment to Reduce the Risk of Breast Cancer Returning
+ FDA Unveils Plan to Eliminate Orphan Designation Backlog
+ FDA Investigates Findings of Hepatitis A Linked to Frozen Tuna
+ FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia
+ FDA Approves First Cancer Treatment for Any Solid Tumor With a Specific Genetic Feature
+ FDA Approves Drug to Treat ALS
+ FDA Approves Urea Cycle Disorder Treatment for Use in Children as Young as Two Months
+ Novartis Receives FDA Approval for Rydapt® in Newly Diagnosed FLT3-mutated Acute Yeloid Leukemia (AML)

Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions